Pill to Treat MS Reduces Swelling by 40 Percent

There has been a new pill that currently is undergoing extensive trials that may someday provide an alternate and most welcome treatment for multiple sclerosis. As most treatments for MS today are given as injections. This new pill may someday provide an alternative oral treatment that many Ms patients would surely welcome with open arms.

The said pill contains the new drug called laquinimod. The said drug has been able to improve the condition of patients with relapse-emitting MS showing only a few side effects. Multiple sclerosis is an auto-immune disease which is characterized by the destruction of myelin, the insulation tissue surrounding the nerve fibers in the central nervous system by the body’s own immune system. This leads to short circuits in the brain as the nerve cells cannot send the right signals to the brain with damaged myelin. Relapse-emitting MS is one of the most common types of the disease that affects a number of people all over the world.

So far treatments available for relapse-emitting MS requires the drugs to be injected into patients. This can make such treatments very inconvenient for some patients which might lead them not to consider such treatments at all. With laquinimod, patients can now consider another alternative. This time laquinimod come sin a pill that patients may be able to take orally.

In the study, the new pill was given on a daily basis to MS patients and was found to reduce inflammation in the brain caused by MS by as much as 40 percent as compared to a non-active placebo. The said drug has undergone a Phase II trial in 51 centers in nine countries led by Italian expert Professor Giancarlo Comi of the University Vita-Salute in Milan, Italy.

In the said trial, 306 MS patients were divided into groups that were given either a placebo or doses of laquinimod. Subsequent brains scans and health checks revealed that those given with the new laquinimod showed fewer brain lesions and reduced swelling by as much as 40 percent than patients had before the said clinical trial.



You can leave a response, or trackback from your own site.

Leave a Reply